First Hepatitis B Functional-Cure Treatment Approved in US: What Hibsago Means for Patients

Clinical researcher examining hepatitis B surface antigen and viral DNA monitoring charts in a laboratory, illustrating the Hibsago functional-cure treatment breakthrough

MEDISEARCHER NEWS

United States / European Union · Hepatitis B · 7 November 2026

In brief

  • The US Food and Drug Administration approved Hibsago (bepirovirsen) on 20 October 2026 for certain adults with chronic hepatitis B.
  • Hibsago is the first FDA-approved antisense oligonucleotide treatment for chronic hepatitis B and offers some patients the possibility of a functional cure.
  • Across two Phase III trials, approximately 19% of treated patients maintained the defined functional-cure response 24 weeks after stopping all hepatitis B treatment, compared with none receiving placebo.
  • The treatment is used alongside existing antiviral medication and is intended for a specific group of adults without cirrhosis.
  • Important safety risks include serious liver reactions and potentially dangerous reductions in platelet counts, requiring regular monitoring.
  • The European Medicines Agency accepted bepirovirsen for regulatory review in March 2026, but EU marketing authorisation has not yet been granted.

For decades, treatment for chronic hepatitis B has largely focused on suppressing the virus rather than allowing patients to stop medication while maintaining long-term control.

That could now begin to change for some patients.

On 20 October 2026, the US Food and Drug Administration (FDA) approved Hibsago (bepirovirsen), a new treatment that gives certain adults with chronic hepatitis B the possibility of achieving what researchers call a functional cure.

Unlike a complete eradication of hepatitis B from the body, functional cure means that key markers of infection become undetectable and remain so for a defined period after treatment ends.

The approval is significant because most people receiving conventional treatment for chronic hepatitis B require long-term antiviral medication. Hibsago introduces a time-limited additional treatment that may allow a proportion of carefully selected patients to discontinue all hepatitis B therapy under medical supervision.

However, the results also require perspective. Around four in five treated patients did not achieve the functional-cure endpoint, and the medicine carries important safety warnings.

What is Hibsago and why is its approval important?

Hibsago is the brand name for bepirovirsen, a treatment developed by GSK in collaboration with Ionis Pharmaceuticals.

It belongs to a class of medicines called antisense oligonucleotides.

These medicines use short, specially designed strands of genetic material to interfere with the molecular instructions involved in producing particular proteins.

In chronic hepatitis B, bepirovirsen targets viral RNA involved in hepatitis B replication and the production of viral proteins, including hepatitis B surface antigen (HBsAg).

Reducing these viral components may help the immune system regain control of the infection.

The FDA described Hibsago as the first approved antisense oligonucleotide treatment for chronic hepatitis B.

The important difference from existing antiviral therapy is not simply that Hibsago suppresses viral activity. Its clinical programme specifically investigated whether patients could maintain control of hepatitis B after treatment was stopped.

What does a functional cure for hepatitis B actually mean?

The term “functional cure” can be confusing because it does not mean that every trace of hepatitis B has been eliminated from the body.

Hepatitis B can leave persistent viral genetic material inside liver cells, even when standard blood tests no longer detect active infection markers.

Researchers therefore distinguish between a functional cure and complete elimination of all viral material.

In the Hibsago clinical trials, functional cure required:

  • Loss of detectable hepatitis B surface antigen (HBsAg).
  • Undetectable hepatitis B virus DNA in the blood.
  • Maintenance of both findings for at least 24 weeks after stopping all hepatitis B treatment.

This represents a meaningful clinical milestone because the patient is maintaining control of the infection without continuing antiviral medication during the assessment period.

However, it does not guarantee that hepatitis B can never reactivate, nor does it remove every potential long-term liver-health risk.

Patients who achieve functional cure may still need follow-up and liver-cancer surveillance according to their individual medical history and clinical risk.

How effective was Hibsago in clinical trials?

The FDA approval was supported by two large Phase III clinical trials known as B-Well 1 and B-Well 2.

These international, randomised, double-blind studies evaluated bepirovirsen in adults with chronic hepatitis B whose infection was already suppressed by conventional antiviral treatment.

Participants received bepirovirsen or placebo in addition to their existing antiviral medication.

Hibsago was administered as a subcutaneous injection for up to 24 weeks.

Participants continued their existing antiviral medication for at least another 24 weeks after completing Hibsago. Those meeting defined laboratory and clinical criteria could subsequently discontinue antiviral therapy under supervision.

Across the two trials, approximately 24% of Hibsago recipients met the criteria to stop their existing antiviral medication, compared with none in the placebo groups.

At the primary assessment point, approximately 19% of Hibsago recipients maintained the defined functional-cure response for 24 weeks after stopping all hepatitis B treatment.

No placebo recipients achieved that endpoint.

Clinical outcome Hibsago plus antiviral therapy Placebo plus antiviral therapy
Eligible to stop existing antiviral treatment Approximately 24% 0%
Functional cure 24 weeks after stopping all treatment Approximately 19% 0%

These results represent an important improvement over continued viral suppression alone in the populations studied.

They do not mean that Hibsago cures 19% of everyone living with hepatitis B. The trials involved selected patients who were already receiving antiviral treatment and met specific eligibility requirements.

Most treated participants did not achieve the functional-cure endpoint.

New November 2026 data: did the response last longer?

Additional results presented at The Liver Meeting 2026 provide encouraging evidence about the durability of the treatment response.

Among participants who achieved functional cure, discontinued nucleos(t)ide analogue therapy and completed the extended follow-up, approximately 90% to 92% maintained that response through 48 weeks after stopping all hepatitis B treatment.

This finding is important because a functional cure is more valuable if viral control persists beyond the original 24-week assessment period.

However, the percentage refers to the subgroup of patients who had already achieved functional cure and completed follow-up. It must not be interpreted as a 90% cure rate among everyone who received Hibsago.

These extended follow-up results were reported at a medical conference in November 2026. They should be distinguished from the primary Phase III findings supporting FDA approval, and longer-term outcomes will remain important.

Who is eligible for Hibsago in the United States?

Hibsago is not approved for every person with hepatitis B.

Under the FDA-approved indication, eligible patients must be adults with chronic hepatitis B who:

  • do not have liver cirrhosis;
  • have already received nucleoside or nucleotide analogue antiviral treatment for at least six months;
  • have suppressed hepatitis B virus DNA levels; and
  • have hepatitis B surface antigen (HBsAg) levels of 3,000 IU/mL or less, measured using an FDA-authorised test.

The FDA also authorised the Roche Elecsys HBsAg II quant II RxDx assay as a companion diagnostic to support patient selection and treatment monitoring.

These requirements mean that treatment decisions depend on specialist assessment and laboratory results.

Patients should not assume they qualify simply because they have been diagnosed with chronic hepatitis B.

Does Hibsago replace existing hepatitis B medication?

No. Hibsago is initially used in combination with existing antiviral treatment.

Conventional hepatitis B medicines, including nucleoside and nucleotide analogues, suppress viral replication and can substantially reduce the risk of serious liver complications.

However, many patients need to continue taking these medicines for years or indefinitely.

Hibsago introduces a different strategy: adding a finite course of treatment with the aim of achieving a sustained response that may eventually allow antiviral therapy to be stopped.

In the clinical trials, patients continued their existing antiviral medicine after the Hibsago treatment course and could stop it only if they met specific criteria.

Stopping hepatitis B antiviral medication without appropriate medical supervision can be dangerous because viral activity and liver inflammation may return.

What are the risks and side effects of Hibsago?

Despite its potential benefits, Hibsago is not a low-risk treatment.

The FDA-approved prescribing information includes a boxed warning covering serious liver reactions and thrombocytopenia, a reduction in blood platelet counts.

Platelets help blood clot, and severe thrombocytopenia can cause dangerous bleeding.

The medicine can also cause significant increases in liver enzymes, including episodes of liver inflammation during treatment.

Additional warnings include worsening kidney function, serious inflammatory reactions such as vasculitis and risks associated with incorrect injection administration.

Common adverse reactions include:

  • injection-site reactions;
  • fever;
  • fatigue; and
  • headache.

Patients require blood testing before and during treatment, including monitoring of liver function, platelet counts and kidney function.

The US prescribing information requires at least weekly platelet monitoring during the treatment period, with more frequent testing in certain circumstances.

Hibsago is contraindicated in patients with certain liver conditions and in those whose platelet count is below the specified treatment threshold.

These risks reinforce why treatment must be managed by an appropriately qualified healthcare professional.

Is Hibsago approved in Europe?

Not yet.

The European Medicines Agency accepted GSK’s marketing authorisation application for bepirovirsen in March 2026.

That means the medicine entered the European regulatory assessment process, but acceptance of an application is not the same as approval.

As of 7 November 2026, Hibsago has not received European Union marketing authorisation.

The EMA review is particularly relevant because chronic hepatitis B remains a substantial public-health concern across Europe.

According to figures cited in GSK’s European regulatory announcement, approximately 3.2 million people in Europe live with chronic hepatitis B.

If the EMA assessment results in a positive recommendation and the European Commission grants marketing authorisation, the medicine could become eligible for commercial supply in EU member states under the approved conditions.

However, EU authorisation would not automatically guarantee immediate patient access in every country.

National pricing, reimbursement and healthcare-system decisions would still affect when and how eligible patients could receive treatment.

What about Australia and other countries?

Australia’s Therapeutic Goods Administration has also accepted an application to evaluate Hibsago.

The Australian application was accepted in June 2026 for a proposed indication involving adults with chronic hepatitis B who do not have cirrhosis, are already receiving antiviral therapy and meet specified hepatitis B surface antigen criteria.

Acceptance for evaluation does not mean the medicine has been approved for Australian patients.

Regulatory decisions, commercial launch arrangements and reimbursement decisions are separate steps.

Hibsago has also received approval in Japan, making the United States one of the first major markets to authorise the treatment.

Could Hibsago reduce the risk of liver cancer?

Chronic hepatitis B is a major cause of cirrhosis and liver cancer.

Achieving sustained control of the infection and loss of hepatitis B surface antigen is generally considered a desirable long-term treatment goal.

However, the Hibsago Phase III trials were designed primarily to measure functional-cure outcomes, not to establish whether treatment directly prevents liver cancer or extends survival.

It would therefore be premature to claim that Hibsago has been proven to prevent liver cancer.

Longer-term studies and real-world follow-up will be important to determine whether the treatment’s virological benefits translate into fewer serious liver complications.

People with existing liver damage or other risk factors may still require liver-cancer surveillance even after achieving functional cure.

Does this mean hepatitis B can now be cured?

The answer depends on what is meant by “cured.”

For a proportion of eligible patients, Hibsago offers a clinically demonstrated opportunity to achieve functional cure: sustained disappearance of detectable hepatitis B surface antigen and viral DNA after treatment has ended.

That is a major advance in a disease where long-term viral suppression has historically been the main treatment objective.

But it is not equivalent to complete elimination of hepatitis B genetic material from every infected cell.

It is also not effective in every patient, and it does not remove the need for careful monitoring.

Researchers are continuing to investigate additional treatment combinations and strategies that could increase functional-cure rates and extend the benefits to broader groups of patients.

What happens next for hepatitis B treatment?

The FDA approval represents an important transition from clinical-trial research into regulated treatment for selected patients in the United States.

Several developments will now determine its broader impact:

  • European authorisation: the outcome of the EMA review will determine whether Hibsago can receive EU-wide marketing authorisation.
  • National reimbursement: pricing and coverage decisions will influence practical access in individual countries.
  • Longer-term evidence: additional follow-up will help establish how durable functional cure remains over time.
  • Safety monitoring: real-world use will provide further information about the balance between treatment benefits and serious adverse reactions.
  • Future treatment strategies: additional therapies and combinations may improve functional-cure rates beyond those achieved in the current trials.

For patients, the most important message is that Hibsago creates a new possibility, but not a universal cure.

People receiving hepatitis B treatment should continue their prescribed medication and discuss any questions about newer therapies with their treating specialist.

Frequently asked questions

Is there now an FDA-approved functional cure for hepatitis B?

Yes. Hibsago (bepirovirsen) was approved by the FDA on 20 October 2026 for selected adults with chronic hepatitis B. It gives some patients the possibility of achieving functional cure after a defined course of treatment, but most treated patients did not achieve that endpoint in clinical trials.

What percentage of patients achieved functional cure with Hibsago?

Approximately 19% of Hibsago-treated participants achieved the defined functional-cure endpoint 24 weeks after stopping all hepatitis B treatment, compared with none receiving placebo in the Phase III trials.

Can Hibsago eliminate hepatitis B permanently?

Hibsago can help some patients achieve sustained loss of detectable hepatitis B surface antigen and viral DNA after treatment ends. However, functional cure is not the same as complete elimination of all viral genetic material, and lifelong freedom from reactivation cannot be guaranteed.

Is Hibsago available in the European Union?

Hibsago is under European regulatory review but has not yet received EU marketing authorisation as of 7 November 2026.

Can patients stop taking tenofovir or entecavir after Hibsago?

Some patients may become eligible to discontinue existing antiviral treatment after completing Hibsago, but only when specific clinical and laboratory criteria are met. Patients must not stop hepatitis B medication without medical supervision.

What are the most serious Hibsago side effects?

The FDA prescribing information includes boxed warnings for serious liver reactions and potentially dangerous reductions in platelet counts. Patients require regular laboratory monitoring during treatment.


Reviewed by: Dr Mattias Hagman, PhD

Editorial review: This article was prepared using the FDA’s October 2026 approval announcement, the US prescribing information for Hibsago, Phase III B-Well clinical-trial findings, the European Medicines Agency application announcement, Australian regulatory information and November 2026 extended follow-up reporting. It distinguishes functional cure from complete viral eradication and separates confirmed regulatory approval from applications still under review.

Last reviewed: 7 November 2026

Sources and verification

MediSearcher reviewed the following regulatory and clinical sources:

MediSearcher provides general information about medicines, clinical research and healthcare regulation. Hibsago is not suitable for every patient with chronic hepatitis B and carries important safety warnings. Functional cure does not mean complete eradication of the virus or guaranteed lifelong protection against reactivation. This article does not provide personal medical advice. Patients should consult their treating healthcare professional and should never discontinue hepatitis B antiviral medication without medical supervision.